

**PB 71 of 2024**

**National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (July Update) Instrument 2024**

*National Health Act 1953*

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 27 June 2024

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Highly Specialised Drugs Program) Special Arrangement 2021  
(PB 27 of 2021) 2

1. Name
2. This instrument is the *National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (July Update) Instrument 2024.*
3. This instrument may also be cited as PB 71 of 2024.
4. Commencement
5. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 July 2024* | *1 July 2024* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
2. Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

1. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

1. Part 1, Division 1, Section 6, definition for “CAR drug”

*substitute:*

***CAR drug***(short for Complex Authority Required drug) means any of the following highly specialised drugs:

* 1. abatacept;
  2. adalimumab;
  3. ambrisentan;
  4. anifrolumab;
  5. avatrombopag;
  6. azacitidine;
  7. benralizumab;
  8. bosentan;
  9. burosumab;
  10. daunorubicin with cytarabine;
  11. difelikefalin;
  12. dupilumab;
  13. eculizumab;
  14. elexacaftor with tezacaftor and with ivacaftor, and ivacaftor;
  15. eltrombopag;
  16. epoprostenol;
  17. etanercept;
  18. iloprost;
  19. infliximab;
  20. ivacaftor;
  21. lenalidomide;
  22. lumacaftor with ivacaftor;
  23. macitentan;
  24. mepolizumab;
  25. midostaurin;
  26. nusinersen;
  27. omalizumab;
  28. onasemnogene abeparvovec;
  29. pasireotide;
  30. pegcetacoplan;
  31. pegvisomant;
  32. pomalidomide;
  33. ravulizumab;
  34. riociguat;
  35. risdiplam;
  36. romiplostim;
  37. selexipag;
  38. sildenafil;
  39. tadalafil;
  40. teduglutide;
  41. tezacaftor with ivacaftor and ivacaftor;
  42. tocilizumab;
  43. ustekinumab;
  44. vedolizumab.

1. Schedule 1, after entry for Anakinra

*insert:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Anifrolumab | Solution concentrate for I.V. infusion 300 mg in 2 mL | Injection | Saphnelo | C15387 C15388 C15426 |  | See Schedule 2 | See Schedule 2 |

1. Schedule 1, entry for Avatrombopag
2. *omit from the column headed “Circumstances”:* C14101
3. *omit from the column headed “Circumstances”:* C14131 C14132
4. *insert in numerical order in the column headed “Circumstances”:* C15340 C15375
5. Schedule 1, entry for Benralizumab

*omit from the column headed “Circumstances”:* C11841 C11842 C11892 C11893 *substitute:* C15353 C15376 C15383 C15444

1. Schedule 1, entry for Buprenorphine

*substitute:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Buprenorphine | Injection (modified release) 8 mg in 0.16 mL pre‑filled syringe | Injection | Buvidal Weekly | C15385 |  | 4 | 5 |
|  | Injection (modified release) 16 mg in 0.32 mL pre‑filled syringe | Injection | Buvidal Weekly | C15385 |  | 4 | 5 |
|  | Injection (modified release) 24 mg in 0.48 mL pre‑filled syringe | Injection | Buvidal Weekly | C15385 |  | 4 | 5 |
|  | Injection (modified release) 32 mg in 0.64 mL pre‑filled syringe | Injection | Buvidal Weekly | C15385 |  | 4 | 5 |
|  | Injection (modified release) 64 mg in 0.18 mL pre‑filled syringe | Injection | Buvidal Monthly | C15356 |  | 1 | 5 |
|  | Injection (modified release) 96 mg in 0.27 mL pre‑filled syringe | Injection | Buvidal Monthly | C15356 |  | 1 | 5 |
|  | Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe | Injection | Sublocade | C15439 |  | 1 | 5 |
|  | Injection (modified release) 128 mg in 0.36 mL pre‑filled syringe | Injection | Buvidal Monthly | C15356 |  | 1 | 5 |
|  | Injection (modified release) 160 mg in 0.45 mL pre‑filled syringe | Injection | Buvidal Monthly | C15356 |  | 1 | 5 |
|  | Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe | Injection | Sublocade | C15439 |  | 1 | 5 |
|  | Tablet (sublingual) 400 micrograms (as hydrochloride) | Sublingual | Subutex | C15355 |  | 28 | 5 |
|  | Tablet (sublingual) 2 mg (as hydrochloride) | Sublingual | Subutex | C15355 |  | 84 | 5 |
|  | Tablet (sublingual) 8 mg (as hydrochloride) | Sublingual | Subutex | C15355 |  | 112 | 5 |

1. Schedule 1, entry for Buprenorphine with naloxone

*substitute:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Buprenorphine with naloxone | Film (soluble) 2 mg (as hydrochloride)‑0.5 mg (as hydrochloride) | Sublingual | Suboxone Film 2/0.5 | C15355 |  | 84 | 5 |
|  | Film (soluble) 8 mg (as hydrochloride)‑2 mg (as hydrochloride) | Sublingual | Suboxone Film 8/2 | C15355 |  | 112 | 5 |

1. Schedule 1, entry for Ciclosporin in the form Capsule 10 mg
2. *omit from the column headed “Circumstances”:* **C15259 C15300**
3. *insert in numerical order in the column headed “Circumstances”:* **C15360 C15361**
4. Schedule 1, entry for Ciclosporin in each of the forms: Capsule 25 mg, Capsule 50 mg; and Capsule 100 mg
   1. *omit from the column headed “Circumstances” (all instances):* **C15259 C15300**
   2. *insert in numerical order in the column headed “Circumstances” (all instances):* **C15360 C15361**
5. Schedule 1, entry for Ciclosporin in the form Oral liquid 100 mg per mL, 50 mL
6. *omit from the column headed “Circumstances”:* **C15259 C15300**
7. *insert in numerical order in the column headed “Circumstances”:* **C15360 C15361**
8. Schedule 1, after entry for Darunavir with cobicistat, emtricitabine and tenofovir alafenamide

*insert:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Daunorubicin with cytarabine | Powder for I.V. infusion containing daunorubicin 44 mg (as hydrochloride) and cytarabine 100 mg | Injection | Vyxeos | C15390 C15413 |  | See Schedule 2 | See Schedule 2 |

1. Schedule 1, entry for Dupilumab in the form Injection 200 mg in 1.14 mL single dose pre‑filled syringe

*omit from the column headed “Circumstances”:* C11897 C11924 C11964 *substitute:* C15341 C15348 C15433

1. Schedule 1, entry for Dupilumab in the form Injection 300 mg in 2 mL single dose pre‑filled syringe

*omit from the column headed “Circumstances”:* C11844 C11924 C11926 *substitute:* C15348 C15424 C15425

1. Schedule 1, entry for Mepolizumab in the form Injection 100 mg in 1 mL single dose pre‑filled pen
2. *omit from the column headed “Circumstances”:* C11841 C11842 C11848 C11950
3. *insert in numerical order in the column headed “Circumstances”:* C15344 C15353 C15376 C15400
4. Schedule 1, entry for Mepolizumab in the form Powder for injection 100 mg

*omit from the column headed “Circumstances”:* C11841 C11842 C11848 C11950 *substitute:* C15344 C15353 C15376 C15400

1. Schedule 1, entry for Methadone

*substitute:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Methadone | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL | Oral | Aspen Methadone Syrup | C15358 |  | 840 | 5 |
|  |  |  | Biodone Forte | C15358 |  | 840 | 5 |
|  | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL | Oral | Aspen Methadone Syrup | C15358 |  | 840 | 5 |
|  |  |  | Biodone Forte | C15358 |  | 840 | 5 |

1. Schedule 1, after entry for Octreotide in the form Injection 50 micrograms (as acetate) in 1 mL *[Brand: Sandostatin 0.05]*

*insert:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Injection 50 micrograms (as acetate) in 1 mL (S19A) | Injection | Octreotide Acetate Omega (Canada) | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 |

1. Schedule 1, after entry for Octreotide in the form Injection 100 micrograms (as acetate) in 1 mL *[Brand: Sandostatin 0.1]*

*insert:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Injection 100 micrograms (as acetate) in 1 mL (S19A) | Injection | Octreotide Acetate Omega (Canada) | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 |

1. Schedule 1, entry for Octreotide in the form Injection 500 micrograms (as acetate) in 1 mL

*insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | Octreotide Acetate Omega (Canada) | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 |

1. Schedule 1, entry for Omalizumab in the form Injection 75 mg in 0.5 mL single dose pre‑filled syringe

*omit from the column headed “Circumstances”:* C10223 C10226 C10265 C11841 C11846 C11847 C11902 *substitute:* C15346 C15347 C15350 C15352 C15376 C15401 C15403

1. Schedule 1, entry for Omalizumab in the form Injection 150 mg in 1 mL single dose pre‑filled syringe
2. *omit from the column headed “Circumstances”:* C10223 C10226 C10265 C11841 C11846 C11847 C11902
3. *insert in numerical order in the column headed “Circumstances”:* C15346 C15347 C15350 C15352 C15376 C15401 C15403
4. Schedule 1, entry for Selinexor in the form Tablet 20 mg *[Maximum Quantity: 16; Number of Repeats: 2]*
5. *omit from the column headed “Circumstances”:* C14022
6. *omit from the column headed “Circumstances”:* C14037
7. *omit from the column headed “Purposes”:* P14022
8. Schedule 1, entry for Selinexor in the form Tablet 20 mg *[Maximum Quantity: 20; Number of Repeats: 2]*
9. *omit from the column headed “Circumstances”:* C14022
10. *omit from the column headed “Circumstances”:* C14037
11. *omit from the column headed “Purposes”:* P14037
12. Schedule 1, entry for Selinexor in the form Tablet 20 mg *[Maximum Quantity: 32; Number of Repeats: 2]*
13. *omit from the column headed “Circumstances”:* C14022
14. *omit from the column headed “Circumstances”:* C14037
15. Schedule 1, entry for Sevelamer in the form Tablet containing sevelamer carbonate 800 mg

*insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | ARX-SEVELAMER | C5530 C9762 |  | 360 | 5 |

1. Schedule 2, after entry Ambrisentan

*insert:*

|  |  |  |  |
| --- | --- | --- | --- |
| Anifrolumab | C15387 C15388 C15426 | 1 | 5 |

1. Schedule 2, entry for Avatrombopag
2. *omit from the column headed “Circumstances”:* **C14101**
3. *omit from the column headed “Circumstances”:* **C14131 C14132**
4. *insert in numerical order in the column headed “Circumstances”:* **C15340 C15375**
5. Schedule 2, entry for Benralizumab *[Maximum Quantity: 1; Maximum Repeats: Sufficient for 32 weeks of treatment]*

*omit from the column headed “Circumstances”:* **C11841 C11892 C11893** *substitute:* **C15376 C15383 C15444**

1. Schedule 2, entry for Benralizumab *[Maximum Quantity: 1; Maximum Repeats: Sufficient for 24 weeks of treatment]*

*omit from the column headed “Circumstances”:* **C11842** *substitute:* **C15353**

1. Schedule 2, after entry for Burosumab

*insert:*

|  |  |  |  |
| --- | --- | --- | --- |
| Daunorubicin with cytarabine | C15390 | 2 | 3 |
|  | C15413 | 3 | 4 |

1. Schedule 2, entry for Dupilumab *[Maximum Quantity: 1 pack; Maximum Repeats: Sufficient for 32 weeks of treatment]*

*omit from the column headed “Circumstances”:* **C11844 C11897 C11926 C11964** *substitute:* **C15341 C15424 C15425 C15433**

1. Schedule 2, entry for Dupilumab *[Maximum Quantity: 1 pack; Maximum Repeats: Sufficient for 24 weeks of treatment]*

*omit from the column headed “Circumstances”:* **C11924** *substitute:* **C15348**

1. Schedule 2, entry for Mepolizumab *[Maximum Quantity: 1; Maximum Repeats: Sufficient for 32 weeks of treatment]*

*omit from the column headed “Circumstances”:* **C11841 C11848 C11950** *substitute:* **C15344 C15376 C15400**

1. Schedule 2, entry for Mepolizumab *[Maximum Quantity: 1; Maximum Repeats: Sufficient for 24 weeks of treatment]*

*omit from the column headed “Circumstances”:* **C11842** *substitute:* **C15353**

1. Schedule 2, entry for Omalizumab

*substitute:*

|  |  |  |  |
| --- | --- | --- | --- |
| Omalizumab | C7055 | 2 | 2 |
|  | C7046 | 2 | 5 |
|  | C15347 C15352 | 1 | Sufficient for 24 weeks of treatment |
|  | C15346 C15376 C15401 | 1 | Sufficient for 32 weeks of treatment |
|  | C15350 C15403 | 1 | Sufficient for 28 weeks of treatment |

1. Schedule 3, after entry for Anakinra

*insert:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Anifrolumab | C15387 |  | Systemic lupus erythematosus  Continuing or recommencement of treatment (within 12 months of a treatment break)  Patient must have previously been issued with an authority prescription for this drug for this condition; AND  Patient must be responding to treatment if they have received less than 12 months of treatment with this drug for this condition; OR  Patient must have attained a Lupus Low Disease Activity State (LLDAS) and maintained this state while on treatment.  Must be treated by a specialist physician experienced in the management of this condition.  Lupus Low Disease Activity State (LLDAS) is defined as:  (a) Total SLEDAI-2K of not greater than 4, with no major activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever); and  (b) No new features of lupus disease activity compared with the previous assessment, and  (c) Physician Global Assessment (PGA) of not greater than 1, and  (d) Current prednisolone (or equivalent) dose of not greater than 7.5 mg daily, and  (e) Well tolerated standard maintenance doses of anti-malarial and immunosuppressive drugs are allowed.  Where retreatment with anifrolumab after a break in PBS-subsidised treatment with anifrolumab is being sought, the date of cessation of the previous treatment course with anifrolumab must be included in the application. Recommencement of treatment with anifrolumab for severe SLE is within 12 months from the date that treatment was ceased. | Compliance with Authority Required procedures |
|  | C15388 |  | Systemic lupus erythematosus  Initial treatment  Patient must have a confirmed and documented diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) SLE Classification Criteria 2019; AND  Patient must have persistent disease activity as supported by a SLE Disease Activity Index 2000 (SLEDAI-2K) score of at least 10 points; AND  Patient must be currently receiving hydroxychloroquine, with treatment received for at least 12 weeks, unless contraindicated/intolerant necessitating treatment withdrawal; AND  Patient must be currently receiving immunosuppressant medication, with treatment received for at least 12 weeks, with either: (i) minimum dose of methotrexate 20 mg per week, (ii) azathioprine 100 mg per day, (iii) mycophenolate 1,000 mg per day unless contraindicated/intolerant necessitating treatment withdrawal; AND  Patient must be currently receiving prednisolone or equivalent of at least 7.5 mg per day, with treatment received for at least 4 weeks, unless contraindicated/intolerant necessitating treatment withdrawal; AND  Patient must not have either: (i) severe active lupus nephritis, (ii) severe active central nervous system systemic lupus erythematosus.  Must be treated by a specialist physician experienced in the management of this condition.  If prednisolone or equivalent is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated of at least 7.5 mg per day, the patient must have received at least 12 weeks of continuous treatment with each of at least 2 of the following: (i) hydroxychloroquine; (ii) methotrexate at a dose of at least 20 mg per week; (iii) azathioprine at a dose of at least 100 mg per day; (iv) mycophenolate at a dose of at least 1,000 mg per day.  Where two of: (i) hydroxychloroquine; (ii) methotrexate at a dose of at least 20 mg per week; or (iii) azathioprine at a dose of at least 100 mg per day; (iv) mycophenolate at a dose of at least 1,000 mg per day, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to prednisolone or equivalent: at least one of the remaining tolerated therapies must be trialled at a minimum dose as mentioned above.  If the patient has a contraindication/severe intolerance to each of: (i) prednisolone or equivalent of at least 7.5 mg per day; (ii) hydroxychloroquine; (iii) methotrexate at a dose of at least 20 mg per week; (iv) azathioprine at a dose of at least 100 mg per day; (v) mycophenolate at a dose of at least 1,000 mg per day; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application.  The authority application must be made in writing via HPOS form upload or mail and must include:  (a) details of the ACR/EULAR SLE Classification Criteria 2019 confirming diagnosis of SLE;  (b) details (date and score) of the completed SLEDAI-2K score sheet;  (c) details of current systemic therapy used (dosage, date of commencement and duration of therapy including prior anifrolumab use);  (d) details of contraindication/intolerances to prior therapies (drug name, the degree of toxicity and dose).  All the reports must be documented in the patient's medical records.  If the application is submitted through HPOS form upload or mail, it must include:  (i) A completed authority prescription form; and  (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). | Compliance with Written Authority Required procedures |
|  | C15426 |  | Systemic lupus erythematosus  Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements  Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 July 2024; AND  Patient must have had a confirmed and documented diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) SLE Classification Criteria 2019 prior to commencing therapy with this drug for this condition; AND  Patient must have had persistent disease activity as supported by a SLE Disease Activity Index 2000 (SLEDAI-2K) score of at least 10 points prior to commencing therapy with this drug for this condition; AND  Patient must have been receiving hydroxychloroquine for at least 12 weeks prior to commencing therapy with this drug for this condition; AND  Patient must have been receiving immunosuppressant medication for at least 12 weeks with either (i) minimum dose of methotrexate 20 mg per week (ii) azathioprine 100 mg per day (iii)mycophenolate 1,000 mg per day, prior to commencing therapy with this drug for this condition unless contraindicated/intolerant necessitating treatment withdrawal; AND  Patient must have been receiving prednisolone or equivalent of at least 7.5 mg per day for at least 4 weeks prior to commencing therapy with this drug for this condition unless contraindicated/intolerant necessitating treatment withdrawal; AND  Patient must not have either: (i) severe active lupus nephritis, (ii) severe active central nervous system systemic lupus erythematosus.  Must be treated by a specialist physician experienced in the management of this condition.  If prednisolone or equivalent is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated of at least 7.5 mg per day, the patient must have received at least 12 weeks of continuous treatment with each of at least 2 of the following: (i) hydroxychloroquine; (ii) methotrexate at a dose of at least 20 mg per week; (iii) azathioprine at a dose of at least 100 mg per day; (iv) mycophenolate at a dose of at least 1,000 mg per day.  Where two of: (i) hydroxychloroquine; (ii) methotrexate at a dose of at least 20 mg per week; or (iii) azathioprine at a dose of at least 100 mg per day; (iv) mycophenolate at a dose of at least 1,000 mg per day, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to prednisolone or equivalent: at least one of the remaining tolerated therapies must be trialled at a minimum dose as mentioned above.  If the patient has a contraindication/severe intolerance to each of: (i) prednisolone or equivalent of at least 7.5 mg per day; (ii) hydroxychloroquine; (iii) methotrexate at a dose of at least 20 mg per week; (iv) azathioprine at a dose of at least 100 mg per day; (v) mycophenolate at a dose of at least 1,000 mg per day; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application.  The authority application must be made in writing via HPOS form upload or mail and must include:  (a) details of the ACR/EULAR SLE Classification Criteria 2019 confirming diagnosis of SLE;  (b) details (date and score) of the completed SLEDAI-2K score sheet;  (c) details of current systemic therapy used (dosage, date of commencement and duration of therapy including prior anifrolumab use);  (d) details of contraindication/intolerances to prior therapies (drug name, the degree of toxicity and dose).  All the reports must be documented in the patient's medical records.  If the application is submitted through HPOS form upload or mail, it must include:  (i) A completed authority prescription form; and  (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria. | Compliance with Written Authority Required procedures |

1. Schedule 3, entry for Avatrombopag
2. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C14101 |  | Severe thrombocytopenia First Continuing treatment or Re‑initiation of interrupted continuing treatment The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND Patient must have demonstrated a sustained platelet response to PBS‑subsidised treatment with this drug for this condition under the Initial treatment or Grandfather treatment restriction if the patient has not had a treatment break, confirmed through a pathology report from an Approved Pathology Authority; OR Patient must have changed treatment from either romiplostim or eltrombopag to this drug under the Balance of Supply/Change of Therapy restriction and demonstrated a sustained response; OR Patient must have demonstrated a sustained platelet response to the most recent PBS‑subsidised treatment with this drug for this condition prior to interrupted treatment, confirmed through a pathology report from an Approved Pathology Authority; AND The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition. For the purposes of this restriction, a sustained response is defined as the patient having the ability to maintain a platelet count sufficient to prevent clinically significant bleeding based on clinical assessment. The platelet count must be conducted no later than 4 weeks from the date of completion of the most recent PBS‑subsidised course of treatment with this drug and must be documented in the patient's medical records. | Compliance with Authority Required procedures |

1. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C14131 |  | Severe thrombocytopenia Balance of supply or change of therapy The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition; AND Patient must have received insufficient therapy with this drug for this condition under the Initial treatment restriction; OR Patient must have received insufficient therapy with this drug for this condition under the First Continuing treatment or Re‑initiation of interrupted continuing treatment restriction; OR Patient must have received insufficient therapy with this drug for this condition under the Second or Subsequent Continuing treatment restriction; OR Patient must have received insufficient therapy with this drug for this condition under the Grandfather treatment restriction; OR Patient must be changing therapy from romiplostim or eltrombopag to this drug for this condition; AND The treatment must provide no more than the balance of up to 24 weeks treatment under this restriction. Patients receiving treatment with romiplostim or eltrombopag may change to avatrombopag under this restriction. | Compliance with Authority Required procedures |
|  | C14132 |  | Severe thrombocytopenia Grandfather treatment The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND Patient must have previously received non‑PBS‑subsidised treatment with this drug for this condition prior to 1 July 2023; AND Patient must have failed to achieve an adequate response to, or be intolerant to, corticosteroid therapy prior to initiating non‑PBS‑subsidised treatment with this drug for this condition; AND Patient must have failed to achieve an adequate response to, or be intolerant to, immunoglobulin therapy prior to initiating non‑PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated a sustained platelet response to the non‑PBS‑subsidised treatment with this drug for this condition; AND The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition. The authority application must be made via the online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include: (a) details of a platelet count supporting the diagnosis of ITP. All reports must be documented in the patient's medical records. If the application is submitted through HPOS form upload or mail, it must include: (i) A completed authority prescription form; and (ii) A completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). The following criteria indicate failure to achieve an adequate response to corticosteroid and/or immunoglobulin therapy and must be demonstrated at the time of initial application; (a) a platelet count of less than or equal to 20,000 million per L; OR (b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range. The platelet count must have been no more than 4 weeks old at the time that non‑PBS‑subsidised treatment with this drug was initiated and must be documented in the patient's medical records. For the purposes of this restriction, a sustained response is defined as the patient having the ability to maintain a platelet count sufficient to prevent clinically significant bleeding based on clinical assessment. A Grandfathered patient may qualify for PBS‑subsidised treatment under this restriction once only. For continuing PBS‑subsidised treatment, a Grandfathered patient must qualify under the First Continuing treatment or Re‑initiation of interrupted continuing treatment criteria. | Compliance with Written Authority Required procedures |

1. *insert in numerical order after existing text:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C15340 |  | Severe thrombocytopenia  Balance of supply or change of therapy  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  The treatment must be the sole PBS-subsidised thrombopoietin receptor agonist (TRA) for this condition; AND  Patient must have received insufficient therapy with this drug for this condition under the Initial treatment restriction; OR  Patient must have received insufficient therapy with this drug for this condition under the First Continuing treatment or Re-initiation of interrupted continuing treatment restriction; OR  Patient must have received insufficient therapy with this drug for this condition under the Second or Subsequent Continuing treatment restriction; OR  Patient must be changing therapy from romiplostim or eltrombopag to this drug for this condition; AND  The treatment must provide no more than the balance of up to 24 weeks treatment under this restriction.  Patients receiving treatment with romiplostim or eltrombopag may change to avatrombopag under this restriction. | Compliance with Authority Required procedures |
|  | C15375 |  | Severe thrombocytopenia  First Continuing treatment or Re-initiation of interrupted continuing treatment  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have demonstrated a sustained platelet response to PBS-subsidised treatment with this drug for this condition under the Initial treatment restriction if the patient has not had a treatment break, confirmed through a pathology report from an Approved Pathology Authority; OR  Patient must have changed treatment from either romiplostim or eltrombopag to this drug under the Balance of Supply/Change of Therapy restriction and demonstrated a sustained response; OR  Patient must have demonstrated a sustained platelet response to the most recent PBS-subsidised treatment with this drug for this condition prior to interrupted treatment, confirmed through a pathology report from an Approved Pathology Authority; AND  The treatment must be the sole PBS-subsidised thrombopoietin receptor agonist (TRA) for this condition.  For the purposes of this restriction, a sustained response is defined as the patient having the ability to maintain a platelet count sufficient to prevent clinically significant bleeding based on clinical assessment.  The platelet count must be conducted no later than 4 weeks from the date of completion of the most recent PBS-subsidised course of treatment with this drug and must be documented in the patient's medical records. | Compliance with Authority Required procedures |

1. Schedule 3, entry for Benralizumab

*substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Benralizumab | C15353 |  | Uncontrolled severe asthma  Continuing treatment  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received this drug as their most recent course of PBS-subsidised biological agent treatment for this condition in this treatment cycle; AND  Patient must have demonstrated or sustained an adequate response to PBS-subsidised treatment with this drug for this condition; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Patient must be aged 12 years or older.  An adequate response to this biological medicine is defined as:  (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline,  OR  (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline or an increase in ACQ-5 score from baseline less than or equal to 0.5.  All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment or the assessment of oral corticosteroid dose, should be made from 20 weeks after the first dose of PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.  The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient's response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment.  A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS-subsidised treatment with this biological medicine for severe asthma within the current treatment cycle.  At the time of the authority application, medical practitioners should request the appropriate number of repeats to provide for a continuing course of this drug sufficient for up to 24 weeks of therapy.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following information must be provided at the time of application and must be documented in the patient's medical records:  (a) if applicable, details of maintenance oral corticosteroid dose; and  (b) a completed Asthma Control Questionnaire (ACQ-5) score. | Compliance with Written Authority Required procedures |
|  | C15376 |  | Uncontrolled severe asthma  Balance of supply  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND  The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR  The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C15383 |  | Uncontrolled severe asthma  Initial treatment - Initial 2 (Change of treatment)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must have received prior PBS-subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND  Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for severe asthma during the current treatment cycle; AND  Patient must have had a blood eosinophil count of at least 300 cells per microlitre and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; OR  Patient must have had a blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  An application for a patient who has received PBS-subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ-5 assessment of the patient's most recent course of PBS-subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine.  An ACQ-5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS-subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  At the time of the authority application, medical practitioners should request up to 4 repeats to provide for an initial course sufficient for up to 32 weeks of therapy, based on a dose of 30 mg every 4 weeks for the first three doses (weeks 0, 4, and 8) then 30 mg every eight weeks thereafter (refer to the TGA-approved Product Information).  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) Asthma Control Questionnaire (ACQ-5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and  (b) details (date and duration of treatment) of prior biological medicine treatment; and  (c) eosinophil count and date; and  (d) if applicable, the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and  (e) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). | Compliance with Written Authority Required procedures |
|  | C15444 |  | Uncontrolled severe asthma  Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must not have received PBS-subsidised treatment with a biological medicine for severe asthma; OR  Patient must have had a break in treatment of at least 12 months from the most recently approved PBS-subsidised biological medicine for severe asthma; AND  Patient must have a diagnosis of asthma confirmed and documented in the patient's medical records by either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma, defined by at least one of the following standard clinical features: (a) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), (b) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, (c) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR  Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma with the details documented in the patient's medical records; AND  Patient must have a duration of asthma of at least 1 year; AND  Patient must have a blood eosinophil count of at least 300 cells per microlitre in the last 12 months; OR  Patient must have blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; AND  Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented in the patient's medical records; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  Optimised asthma therapy includes:  (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated;  AND  (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated.  If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application.  The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:  (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND  (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.  The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within the same treatment cycle.  A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines within the same treatment cycle.  The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle.  There is no limit to the number of treatment cycles that a patient may undertake in their lifetime.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  At the time of the authority application, medical practitioners should request up to 4 repeats to provide for an initial course of benralizumab sufficient for up to 32 weeks of therapy, at a dose of 30 mg every 4 weeks for the first three doses (weeks 0, 4, and 8) then 30 mg every eight weeks thereafter.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) details (treatment, date of commencement, duration of therapy) of prior optimised asthma drug therapy; and  (b) if applicable, details of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to standard therapy according to the relevant TGA-approved Product Information; and  (c) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and  (d) the eosinophil count and date; and  (e) Asthma Control Questionnaire (ACQ-5) score. | Compliance with Written Authority Required procedures |

1. Schedule 3, entry for Buprenorphine

*substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Buprenorphine | C15355 |  | Opioid dependence  The treatment must be within a framework of medical, social and psychological treatment.  A medical practitioner must request a quantity sufficient for up to 28 days of supply per dispensing according to the patient's daily dose. Up to 5 repeats will be authorised. A medical practitioner must not request the maximum listed quantity or number of repeats if lesser quantity or repeats are sufficient for the patient's needs. | Compliance with Authority Required procedures - Streamlined Authority Code 15355 |
|  | C15356 |  | Opioid dependence  Must be treated by a health care professional.  The treatment must be within a framework of medical, social and psychological treatment; AND  Patient must be stabilised on one of the following prior to commencing treatment with this drug for this condition: (i) weekly prolonged release buprenorphine (Buvidal Weekly) (ii) sublingual buprenorphine (iii) buprenorphine/naloxone.  A medical practitioner must not request the maximum listed quantity or number of repeats if lesser quantity or repeats are sufficient for the patient's needs. | Compliance with Authority Required procedures - Streamlined Authority Code 15356 |
|  | C15385 |  | Opioid dependence  Must be treated by a health care professional.  The treatment must be within a framework of medical, social and psychological treatment.  A medical practitioner must not request the maximum listed quantity or number of repeats if lesser quantity or repeats are sufficient for the patient's needs. | Compliance with Authority Required procedures - Streamlined Authority Code 15385 |
|  | C15439 |  | Opioid dependence  Must be treated by a health care professional.  The treatment must be within a framework of medical, social and psychological treatment; AND  Patient must be stabilised on sublingual buprenorphine or buprenorphine/naloxone prior to commencing treatment with this drug for this condition.  A medical practitioner must not request the maximum listed quantity or number of repeats if lesser quantity or repeats are sufficient for the patient's needs. | Compliance with Authority Required procedures - Streamlined Authority Code 15439 |

1. Schedule 3, entry for Buprenorphine with naloxone

*substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Buprenorphine with naloxone | C15355 |  | Opioid dependence  The treatment must be within a framework of medical, social and psychological treatment.  A medical practitioner must request a quantity sufficient for up to 28 days of supply per dispensing according to the patient's daily dose. Up to 5 repeats will be authorised. A medical practitioner must not request the maximum listed quantity or number of repeats if lesser quantity or repeats are sufficient for the patient's needs. | Compliance with Authority Required procedures - Streamlined Authority Code 15355 |

1. Schedule 3, entry for Ciclosporin
   1. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C15259 |  | Severe psoriasis  Management (initiation, stabilisation and review of therapy)  The condition must be ineffective to other systemic therapies; OR  The condition must be inappropriate for other systemic therapies; AND  The condition must have caused significant interference with quality of life.  Must be treated by a medical practitioner who is either: (i) a dermatologist, (ii) a rheumatologist, (iii) general physician; OR  Must be treated by a medical practitioner in consultation with one of the above specialist types who is either an accredited: (i) dermatology registrar, (ii) rheumatology registrar.  For patients who do not demonstrate an adequate response to apremilast, a Psoriasis Area and Severity Index (PASI) assessment must be completed, preferably while on treatment, but no longer than 4 weeks following the cessation of treatment. This assessment will be required for patients who transition to 'biological medicines' for the treatment of 'severe chronic plaque psoriasis'.  This assessment must be documented in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 15259 |
|  | C15300 |  | Severe psoriasis  Management (initiation, stabilisation and review of therapy)  The condition must be ineffective to other systemic therapies; OR  The condition must be inappropriate for other systemic therapies; AND  The condition must have caused significant interference with quality of life.  Must be treated by a medical practitioner who is either: (i) a dermatologist, (ii) a rheumatologist, (iii) general physician; OR  Must be treated by a medical practitioner in consultation with one of the above specialist types who is either an accredited: (i) dermatology registrar, (ii) rheumatology registrar.  For patients who do not demonstrate an adequate response to apremilast, a Psoriasis Area and Severity Index (PASI) assessment must be completed, preferably while on treatment, but no longer than 4 weeks following the cessation of treatment. This assessment will be required for patients who transition to 'biological medicines' for the treatment of 'severe chronic plaque psoriasis'.  This assessment must be documented in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 15300 |

* 1. *insert in numerical order after existing text:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C15360 |  | Severe psoriasis  Management (initiation, stabilisation and review of therapy)  The condition must be ineffective to other systemic therapies; OR  The condition must be inappropriate for other systemic therapies; AND  The condition must have caused significant interference with quality of life.  Must be treated by a medical practitioner who is either: (i) a dermatologist, (ii) a rheumatologist, (iii) general physician; OR  Must be treated by a medical practitioner in consultation with one of the above specialist types who is either an accredited: (i) dermatology registrar, (ii) rheumatology registrar.  For patients who do not demonstrate an adequate response to ciclosporin, a Psoriasis Area and Severity Index (PASI) assessment must be completed, preferably while on treatment, but no longer than 4 weeks following the cessation of treatment. This assessment will be required for patients who transition to 'biological medicines' for the treatment of 'severe chronic plaque psoriasis'.  This assessment must be documented in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 15360 |
|  | C15361 |  | Severe psoriasis  Management (initiation, stabilisation and review of therapy)  The condition must be ineffective to other systemic therapies; OR  The condition must be inappropriate for other systemic therapies; AND  The condition must have caused significant interference with quality of life.  Must be treated by a medical practitioner who is either: (i) a dermatologist, (ii) a rheumatologist, (iii) general physician; OR  Must be treated by a medical practitioner in consultation with one of the above specialist types who is either an accredited: (i) dermatology registrar, (ii) rheumatology registrar.  For patients who do not demonstrate an adequate response to ciclosporin, a Psoriasis Area and Severity Index (PASI) assessment must be completed, preferably while on treatment, but no longer than 4 weeks following the cessation of treatment. This assessment will be required for patients who transition to 'biological medicines' for the treatment of 'severe chronic plaque psoriasis'.  This assessment must be documented in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 15361 |

1. Schedule 3, after entry for Darunavir with cobicistat, emtricitabine and tenofovir alafenamide

*insert:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Daunorubicin with cytarabine | C15390 |  | Acute Myeloid Leukaemia  Consolidation therapy  The treatment must be for consolidation treatment following induction treatment with this product; AND  The condition must be either: (i) newly diagnosed therapy-related acute myeloid leukaemia (AML), (ii) newly diagnosed AML with myelodysplasia-related changes (MRC) (prior myelodysplastic syndromes (MDS) or MDS-related cytogenetic or molecular abnormality); AND  The treatment must not exceed two cycles of consolidation therapy under this restriction.  This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.  The TGA-approved Product Information recommended dosing schedule for consolidation is daunorubicin 29 mg/m2and cytarabine 65 mg/m2on days 1 and 3.  With each authority application, state the body surface area (m2) of the patient.  Based on this prescribe up to:  1 vial where the body surface area is between 1 m2to 1.53 m2  2 vials where the body surface area is above 1.53 m2or up to and including 3.07 m2 | Compliance with Authority Required procedures |
|  | C15413 |  | Acute Myeloid Leukaemia  Induction therapy  Patient must not have received prior chemotherapy as induction therapy for this condition; AND  The condition must be either: (i) newly diagnosed therapy-related acute myeloid leukaemia (AML), (ii) newly diagnosed AML with myelodysplasia-related changes (MRC) (prior myelodysplastic syndromes (MDS) or MDS-related cytogenetic or molecular abnormality); AND  The condition must not be either: (i) internal tandem duplication (ITD); (ii) tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3), mutation positive; AND  Patient must not have favourable cytogenetic risk acute myeloid leukaemia (AML); AND  Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less; AND  The treatment must not exceed two cycles of induction therapy under this restriction.  This drug is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.  The prescriber must confirm whether the patient has newly diagnosed therapy-related AML or AML-MRC. The test result and date of testing must be provided at the time of application and documented in the patient's file.  The TGA-approved Product Information recommended dosing schedule is as follows:  (i) First Induction: daunorubicin 44 mg/m2and cytarabine 100 mg/m2on days 1, 3 and 5  (ii) Second Induction: daunorubicin 44 mg/m2and cytarabine 100 mg/m2on days 1 and 3  With each authority application, state the body surface area (m2) of the patient.  Based on (i) to (ii), prescribe up to:  1 vial where the body surface area is up to and including 1 m2;  2 vials where the body surface area is above 1 m2or up to and including 2 m2;  3 vials where the body surface area is above 2 m2or up to and including 3 m2. | Compliance with Authority Required procedures |

1. Schedule 3, entry for Dupilumab

*substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dupilumab | C15341 |  | Uncontrolled severe asthma  Initial treatment - Initial 2 (Change of treatment)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must have received prior PBS-subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND  Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for severe asthma during the current treatment cycle; AND  Patient must have had a blood eosinophil count of at least 300 cells per microlitre and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; OR  Patient must have had a blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; OR  Patient must have had a total serum human immunoglobulin E of at least 30 IU/mL, measured no more than 12 months prior to initiating PBS-subsidised treatment with a biological medicine for severe asthma, that has past or current evidence of atopy, documented by either: (i) skin prick testing; (ii) an in vitro measure of specific IgE; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  An application for a patient who has received PBS-subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ-5 assessment of the patient's most recent course of PBS-subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine.  An ACQ-5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS-subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment at around 28 weeks, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this biological medicine.  At the time of the authority application, medical practitioners should request up to 8 repeats to provide for an initial course of dupilumab sufficient for up to 32 weeks of therapy, at a dose of 400 mg as an initial dose, followed by 200 mg every 2 weeks thereafter.  A swapping between 200 mg and 300 mg strengths is not permitted as the respective strengths are PBS approved for different patient cohorts.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) Asthma Control Questionnaire (ACQ-5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and  (b) details (treatment, date of commencement, duration of therapy) of prior biological medicine treatment; and  (c) if applicable, the eosinophil count and date; and  (d) if applicable, the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and  (e) if applicable, the IgE result and date; and  (f) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). | Compliance with Written Authority Required procedures |
|  | C15348 |  | Uncontrolled severe asthma  Continuing treatment  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received this drug as their most recent course of PBS-subsidised biological agent treatment for this condition in this treatment cycle; AND  Patient must have demonstrated or sustained an adequate response to PBS-subsidised treatment with this drug for this condition; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Patient must be aged 12 years or older.  An adequate response to this biological medicine is defined as:  (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline,  OR  (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline or an increase in ACQ-5 score from baseline less than or equal to 0.5.  All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment or the assessment of oral corticosteroid dose, should be made from 20 weeks after the first dose of PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and, for the application for continuing therapy to be processed.  The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient's response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment.  A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS-subsidised treatment with this biological medicine for severe asthma within the current treatment cycle.  A swapping between 200 mg and 300 mg strengths is not permitted as the respective strengths are PBS approved for different patient cohorts.  At the time of the authority application, medical practitioners should request the appropriate number of repeats to provide for a continuing course of this drug sufficient for up to 24 weeks of therapy.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following information must be provided at the time of application and must be documented in the patient's medical records:  (a) if applicable, details of maintenance oral corticosteroid dose; and  (b) a completed Asthma Control Questionnaire (ACQ-5) score. | Compliance with Written Authority Required procedures |
|  | C15424 |  | Uncontrolled severe asthma  Initial treatment 1 - (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must not have received PBS-subsidised treatment with a biological medicine for severe asthma; OR  Patient must have had a break in treatment of at least 12 months from the most recently approved PBS-subsidised biological medicine for severe asthma; AND  Patient must have a diagnosis of asthma confirmed and documented in the patient's medical records by either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma, defined by at least one of the following standard clinical features: (a) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), (b) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, (c) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR  Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma with the details documented in the patient's medical records; AND  Patient must have a duration of asthma of at least 1 year; AND  Patient must have been receiving regular maintenance oral corticosteroids (OCS) in the last 6 months with a stable daily OCS dose of 5 to 35 mg/day of prednisolone or equivalent over the 4 weeks prior to treatment initiation; AND  Patient must have blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; OR  Patient must have total serum human immunoglobulin E of at least 30 IU/mL, measured in the last 12 months that has past or current evidence of atopy, documented by either: (i) skin prick testing; (ii) an in vitro measure of specific IgE; AND  Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented in the patient's medical records; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  Optimised asthma therapy includes:  (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated;  AND  (ii) treatment with oral corticosteroids as outlined in the clinical criteria.  If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application.  The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:  (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND  (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.  The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break.  If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within the same treatment cycle.  A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines within the same treatment cycle.  The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle.  There is no limit to the number of treatment cycles that a patient may undertake in their lifetime.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  At the time of the authority application, medical practitioners should request up to 8 repeats to provide for an initial course of dupilumab sufficient for up to 32 weeks of therapy, at a dose of 600 mg as an initial dose, followed by 300 mg every 2 weeks thereafter.  A swapping between 200 mg and 300 mg strengths is not permitted as the respective strengths are PBS approved for different patient cohorts.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) details (treatment, date of commencement, duration of therapy) of prior optimised asthma drug therapy; and  (b) If applicable, details of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to standard therapy according to the relevant TGA-approved Product Information; and  (c) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and  (d) Asthma Control Questionnaire (ACQ-5) score; and  (e) if applicable, the eosinophil count and date; and  (f) if applicable, the IgE result and date. | Compliance with Written Authority Required procedures |
|  | C15425 |  | Uncontrolled severe asthma  Initial treatment - Initial 2 (Change of treatment)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must have received prior PBS-subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND  Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for severe asthma during the current treatment cycle; AND  Patient must have had a blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; OR  Patient must have each of: (i) total serum human immunoglobulin E of at least 30 IU/mL measured no more than 12 months prior to initiating PBS-subsidised treatment with a biological medicine for severe asthma, (ii) past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE in the past 12 months or in the 12 months prior to initiating PBS-subsidised treatment with a biological medicine for severe asthma; AND  Patient must have received regular maintenance oral corticosteroids (OCS) in the last 6 months with a stable daily OCS dose of 5 to 35 mg/day of prednisolone or equivalent over the 4 weeks prior to treatment initiation; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  An application for a patient who has received PBS-subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ-5 assessment of the patient's most recent course of PBS-subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine.  An ACQ-5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS-subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment at around 28 weeks, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this biological medicine.  At the time of the authority application, medical practitioners should request up to 8 repeats to provide for an initial course of dupilumab sufficient for up to 32 weeks of therapy at a dose of 600 mg as an initial dose, followed by 300 mg every 2 weeks thereafter.  A swapping between 200 mg and 300 mg strengths is not permitted as the respective strengths are PBS approved for different patient cohorts.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) Asthma Control Questionnaire (ACQ-5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and  (b) details (treatment, date of commencement, duration of therapy) of prior biological medicine treatment; and  (c) if applicable, the eosinophil count and date; and  (d) if applicable, the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and  (e) if applicable, the IgE result and date; and  (f) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). | Compliance with Written Authority Required procedures |
|  | C15433 |  | Uncontrolled severe asthma  Initial treatment 1 - (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must not have received PBS-subsidised treatment with a biological medicine for severe asthma; OR  Patient must have had a break in treatment of at least 12 months from the most recently approved PBS-subsidised biological medicine for severe asthma; AND  Patient must have a diagnosis of asthma confirmed and documented in the patient's medical records by either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma, defined by at least one of the following standard clinical features: (a) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), (b) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, (c) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR  Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma with the details documented in the patient's medical records; AND  Patient must have a duration of asthma of at least 1 year; AND  Patient must have a blood eosinophil count of at least 300 cells per microlitre in the last 12 months; OR  Patient must have blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; OR  Patient must have total serum human immunoglobulin E of at least 30 IU/mL, measured in the last 12 months that has past or current evidence of atopy, documented by either: (i) skin prick testing; (ii) an in vitro measure of specific IgE; AND  Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented in the patient's medical records; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  Optimised asthma therapy includes:  (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated;  AND  (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated.  If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application.  The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:  (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND  (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.  The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break.  If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within the same treatment cycle.  A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines within the same treatment cycle.  The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle.  There is no limit to the number of treatment cycles that a patient may undertake in their lifetime.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  At the time of the authority application, medical practitioners should request up to 8 repeats to provide for an initial course of dupilumab sufficient for up to 32 weeks of therapy, at a dose of 400 mg as an initial dose, followed by 200 mg every 2 weeks thereafter.  A swapping between 200 mg and 300 mg strengths is not permitted as the respective strengths are PBS approved for different patient cohorts.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) details (treatment, date of commencement, duration of therapy) of prior optimised asthma drug therapy; and  (b) If applicable, details of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to standard therapy according to the relevant TGA-approved Product Information; and  (c) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and  (d) Asthma Control Questionnaire (ACQ-5) score; and  (e) if applicable, the eosinophil count and date; and  (f) if applicable, the IgE result and date. | Compliance with Written Authority Required procedures |

1. Schedule 3, entry for Mepolizumab
   1. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C11841 |  | Uncontrolled severe asthma Balance of supply Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C11842 |  | Uncontrolled severe asthma Continuing treatment Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must have demonstrated or sustained an adequate response to PBS‑subsidised treatment with this drug for this condition; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 12 years or older. An adequate response to this biological medicine is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 score from baseline or an increase in ACQ‑5 score from baseline less than or equal to 0.5. All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment or the assessment of oral corticosteroid dose, should be made at around 20 weeks after the first dose of PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the date of assessment. To avoid an interruption of supply for the first continuing treatment, the assessment should be submitted no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient's response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment. A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS subsidised treatment with this biological medicine for severe asthma within the current treatment cycle. At the time of the authority application, medical practitioners should request the appropriate number of repeats to provide for a continuing course of this drug sufficient for up to 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Asthma Continuing PBS Authority Application ‑ Supporting Information Form which includes: (i) details of maintenance oral corticosteroid dose; or (ii) a completed Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
|  | C11848 |  | Uncontrolled severe asthma Initial treatment ‑ Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for severe asthma; OR Patient must have had a break in treatment from the most recently approved PBS‑subsidised biological medicine for severe asthma; AND Patient must have a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have blood eosinophil count greater than or equal to 300 cells per microlitre in the last 12 months; OR Patient must have blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long‑acting beta‑2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA‑approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) an Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month, AND (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the date of assessment. To avoid an interruption of supply for the first continuing treatment, the assessment should be submitted no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within the same treatment cycle. A treatment break in PBS‑subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines within the same treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with a PBS‑subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. At the time of the authority application, medical practitioners should request up to 7 repeats to provide for an initial course of mepolizumab sufficient for up to 32 weeks of therapy. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Asthma Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) details of prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the eosinophil count and date; and (iv) Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
|  | C11950 |  | Uncontrolled severe asthma Initial treatment ‑ Initial 2 (Change of treatment) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must have received prior PBS‑subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for severe asthma during the current treatment cycle; AND Patient must have had a blood eosinophil count greater than or equal to 300 cells per microlitre and that is no older than 12 months immediately prior to commencing PBS‑subsidised biological medicine treatment for severe asthma; OR Patient must have had a blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS‑subsidised biological medicine treatment for severe asthma; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Asthma (mepolizumab/benralizumab) Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) Asthma Control Questionnaire (ACQ‑5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment; and (iii) eosinophil count and date; and (iv) the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and (v) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). An application for a patient who has received PBS‑subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ‑5 assessment of the patient's most recent course of PBS‑subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine. An ACQ‑5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS‑subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the date of assessment. To avoid an interruption of supply for the first continuing treatment, the assessment should be submitted no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. At the time of the authority application, medical practitioners should request up to 7 repeats to provide for an initial course sufficient for up to 32 weeks of therapy. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. | Compliance with Written Authority Required procedures |

* 1. *insert in numerical order after existing text:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C15344 |  | Uncontrolled severe asthma  Initial treatment - Initial 2 (Change of treatment)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must have received prior PBS-subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND  Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for severe asthma during the current treatment cycle; AND  Patient must have had a blood eosinophil count of at least 300 cells per microlitre and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; OR  Patient must have had a blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS-subsidised biological medicine treatment for severe asthma; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  An application for a patient who has received PBS-subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ-5 assessment of the patient's most recent course of PBS-subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine.  An ACQ-5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS-subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  At the time of the authority application, medical practitioners should request up to 7 repeats to provide for an initial course sufficient for up to 32 weeks of therapy.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) Asthma Control Questionnaire (ACQ-5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and  (b) details (date and duration of treatment) of prior biological medicine treatment; and  (c) eosinophil count and date; and  (d) if applicable, the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and  (e) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). | Compliance with Written Authority Required procedures |
|  | C15353 |  | Uncontrolled severe asthma  Continuing treatment  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received this drug as their most recent course of PBS-subsidised biological agent treatment for this condition in this treatment cycle; AND  Patient must have demonstrated or sustained an adequate response to PBS-subsidised treatment with this drug for this condition; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Patient must be aged 12 years or older.  An adequate response to this biological medicine is defined as:  (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline,  OR  (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline or an increase in ACQ-5 score from baseline less than or equal to 0.5.  All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment or the assessment of oral corticosteroid dose, should be made from 20 weeks after the first dose of PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.  The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient's response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment.  A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS-subsidised treatment with this biological medicine for severe asthma within the current treatment cycle.  At the time of the authority application, medical practitioners should request the appropriate number of repeats to provide for a continuing course of this drug sufficient for up to 24 weeks of therapy.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following information must be provided at the time of application and must be documented in the patient's medical records:  (a) if applicable, details of maintenance oral corticosteroid dose; and  (b) a completed Asthma Control Questionnaire (ACQ-5) score. | Compliance with Written Authority Required procedures |
|  | C15376 |  | Uncontrolled severe asthma  Balance of supply  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND  The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR  The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C15400 |  | Uncontrolled severe asthma  Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must not have received PBS-subsidised treatment with a biological medicine for severe asthma; OR  Patient must have had a break in treatment of at least 12 months from the most recently approved PBS-subsidised biological medicine for severe asthma; AND  Patient must have a diagnosis of asthma confirmed and documented in the patient's medical records by either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma, defined by at least one of the following standard clinical features: (a) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), (b) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, (c) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR  Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma with the details documented in the patient's medical records; AND  Patient must have a duration of asthma of at least 1 year; AND  Patient must have a blood eosinophil count of at least 300 cells per microlitre in the last 12 months; OR  Patient must have blood eosinophil count of at least 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; AND  Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented in the patient's medical records; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  Optimised asthma therapy includes:  (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated;  AND  (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated.  If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application.  The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:  (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND  (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.  The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. To avoid an interruption of supply for the first continuing treatment, the assessment should be provided no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within the same treatment cycle.  A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines within the same treatment cycle.  The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle.  There is no limit to the number of treatment cycles that a patient may undertake in their lifetime.  At the time of the authority application, medical practitioners should request up to 7 repeats to provide for an initial course of mepolizumab sufficient for up to 32 weeks of therapy.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) details (treatment, date of commencement, duration of therapy) of prior optimised asthma drug therapy; and  (b) if applicable, details of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to standard therapy according to the relevant TGA-approved Product Information; and  (c) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and  (d) the eosinophil count and date; and  (e) Asthma Control Questionnaire (ACQ-5) score. | Compliance with Written Authority Required procedures |

1. Schedule 3, entry for Methadone

*substitute:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methadone | C15358 |  | Opioid dependence  The treatment must be within a framework of medical, social and psychological treatment.  A medical practitioner must request a quantity (in millilitres) sufficient for up to 28 days of supply per dispensing according to the patient's daily dose. Up to 5 repeats will be authorised. A medical practitioner must not request the maximum listed quantity or number of repeats if lesser quantity or repeats are sufficient for the patient's needs. | Compliance with Authority Required procedures - Streamlined Authority Code 15358 |

1. Schedule 3, entry for Omalizumab
   1. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C10223 |  | Uncontrolled severe allergic asthma Balance of supply in a patient aged 6 to 12 years Must be treated by a paediatric respiratory physician, clinical immunologist, allergist; or paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician. Patient must have received insufficient therapy with this drug under the Initial treatment restriction to complete 28 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 28 weeks treatment available under the Initial restriction or up to 24 weeks treatment available under the Continuing restriction. | Compliance with Authority Required procedures |
|  | C10226 |  | Uncontrolled severe allergic asthma Continuing treatment Patient must have a documented history of severe allergic asthma; AND Patient must have demonstrated or sustained an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Must be treated by a paediatric respiratory physician, clinical immunologist, allergist; or paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician. An adequate response to omalizumab treatment is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) or ACQ‑IA score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 or ACQ‑IA score from baseline, OR (c) a reduction in the time‑adjusted exacerbation rates compared to the 12 months prior to baseline. All applications for continuing treatment with omalizumab must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) or Asthma Control Questionnaire interviewer administered version (ACQ‑IA) assessment of the patient’s response to the prior course of treatment, the assessment of systemic corticosteroid dose, and the assessment of time‑adjusted exacerbation rate must be made at around 20 weeks after the first dose of PBS‑subsidised omalizumab so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with omalizumab. A patient who fails to respond to a course of PBS‑subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS‑subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased. At the time of the authority application, medical practitioners should request the appropriate quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information), sufficient for 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Severe Allergic Asthma Continuing PBS Authority Application ‑ Supporting Information form which includes details of: (i) maintenance oral corticosteroid dose; and (ii) Asthma Control Questionnaire (ACQ‑5) score; or (iii) Asthma Control Questionnaire interviewer administered version (ACQ‑IA) score. | Compliance with Written Authority Required procedures |
|  | C10265 |  | Uncontrolled severe allergic asthma Initial treatment Patient must have a diagnosis of asthma confirmed and documented by a paediatric respiratory physician, clinical immunologist, or allergist; or paediatrician or general physician experienced in the management of patients with severe asthma in consultation with a respiratory physician, defined by the following standard clinical features: forced expiratory volume (FEV1) reversibility or airway hyperresponsiveness or peak expiratory flow (PEF) variability; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE; AND Patient must have total serum human immunoglobulin E greater than or equal to 30 IU/mL; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 28 weeks of treatment under this restriction. Patient must be aged 6 to less than 12 years. Must be treated by a paediatric respiratory physician, clinical immunologist, allergist; or paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician. Patient must be under the care of the same physician for at least 6 months. Optimised asthma therapy includes: (i) Adherence to optimal inhaled therapy, including high dose inhaled corticosteroid (ICS) and long‑acting beta‑2 agonist (LABA) therapy for at least six months. If LABA therapy is contraindicated, not tolerated or not effective, montelukast, cromoglycate or nedocromil may be used as an alternative; AND (ii) treatment with at least 2 courses of oral or IV corticosteroids (daily or alternate day maintenance treatment courses, or 3‑5 day exacerbation treatment courses), in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications (including those specified in the relevant TGA‑approved Product Information) and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The initial IgE assessment must be no more than 12 months old at the time of application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) An Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month (for children aged 6 to 10 years it is recommended that the Interviewer Administered version ‑ the ACQ‑IA be used), AND (b) while receiving optimised asthma therapy in the previous 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) or ACQ‑IA assessment of the patient’s response to this initial course of treatment, the assessment of oral corticosteroid dose, and the assessment of exacerbation rate should be made at around 24 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with omalizumab. A patient who fails to respond to a course of PBS‑subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS‑subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased. At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab of up to 28 weeks, consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information) to be administered every 2 or 4 weeks. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Severe Allergic Asthma Initial PBS Authority Application ‑ Supporting Information form, which includes the following: (i) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the IgE result; and (iv) Asthma Control Questionnaire (ACQ‑5) score; or (v) Asthma Control Questionnaire interviewer administered version (ACQ‑IA) score. | Compliance with Written Authority Required procedures |
|  | C11841 |  | Uncontrolled severe asthma Balance of supply Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C11846 |  | Uncontrolled severe asthma Initial treatment ‑ Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for severe asthma; OR Patient must have had a break in treatment from the most recently approved PBS‑subsidised biological medicine for severe asthma; AND Patient must have a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE, that is no more than 1 year old at the time of application; AND Patient must have total serum human immunoglobulin E greater than or equal to 30 IU/mL; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long‑acting beta‑2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA‑approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The initial IgE assessment must be no more than 12 months old at the time of application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) an Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month, AND (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the date of assessment. To avoid an interruption of supply for the first continuing treatment, the assessment should be submitted no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for severe asthma within the same treatment cycle. A treatment break in PBS‑subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines for severe asthma within the same treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with a PBS‑subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information) to be administered every 2 or 4 weeks. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Asthma PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) details of prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the IgE result; and (iv) Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Authority Required procedures |
|  | C11847 |  | Uncontrolled severe asthma Continuing treatment Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must have demonstrated or sustained an adequate response to PBS‑subsidised treatment with this drug for this condition; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 12 years or older. An adequate response to omalizumab treatment is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 score from baseline or an increase in ACQ‑5 score from baseline less than or equal to 0.5, OR (c) a reduction in the time‑adjusted exacerbation rates compared to the 12 months prior to baseline (this criterion is only applicable for patients transitioned from the paediatric to the adolescent/adult restriction). All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment, the assessment of oral corticosteroid dose or the assessment of time adjusted exacerbation rate must be made at around 20 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the date of assessment. To avoid an interruption of supply for the first continuing treatment, the assessment should be submitted no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient's response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment. A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS‑subsidised treatment with this biological medicine for severe asthma within the current treatment cycle. At the time of the authority application, medical practitioners should request the appropriate quantity and number of repeats to provide for a continuing course of this biological medicine consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information), sufficient for up to 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Asthma PBS Authority Application and Supporting Information Form which includes details of: (i) maintenance oral corticosteroid dose; or (ii) Asthma Control Questionnaire (ACQ‑5) score including the date of assessment of the patient's symptoms; or (iii) for patients transitioned from the paediatric to the adolescent/adult restrictions, confirmation that the exacerbation rate has reduced. | Compliance with Written Authority Required procedures |
|  | C11902 |  | Uncontrolled severe asthma Initial treatment ‑ Initial 2 (Change of treatment) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must have received prior PBS‑subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for severe asthma during the current treatment cycle; AND Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE in the past 12 months or in the 12 months prior to initiating PBS‑subsidised treatment with a biological medicine for severe asthma; AND Patient must have total serum human immunoglobulin E greater than or equal to 30 IU/mL, measured no more than 12 months prior to initiating PBS‑subsidised treatment with a biological medicine for severe asthma; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Asthma (omalizumab) Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) Asthma Control Questionnaire (ACQ‑5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment; and (iii) the IgE results; and (iv) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ‑5 assessment of the patient's most recent course of PBS‑subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine. An ACQ‑5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS‑subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the date of assessment. To avoid an interruption of supply for the first continuing treatment, the assessment should be submitted no later than 2 weeks prior to the patient completing their current treatment course, unless the patient is currently on a treatment break. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this biological medicine. At the time of the authority application, medical practitioners should request an appropriate maximum quantity based on IgE level and body weight (refer to the TGA‑approved Product Information) to be administered every 2 to 4 weeks and up to 7 repeats to provide for an initial course sufficient for up to 32 weeks of therapy. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. | Compliance with Written Authority Required procedures |

* 1. *insert in numerical order after existing text:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C15346 |  | Uncontrolled severe asthma  Initial treatment - Initial 2 (Change of treatment)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must have received prior PBS-subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND  Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for severe asthma during the current treatment cycle; AND  Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE in the past 12 months or in the 12 months prior to initiating PBS-subsidised treatment with a biological medicine for severe asthma; AND  Patient must have total serum human immunoglobulin E of at least 30 IU/mL, measured no more than 12 months prior to initiating PBS-subsidised treatment with a biological medicine for severe asthma; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ-5 assessment of the patient's most recent course of PBS-subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine.  An ACQ-5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS-subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this biological medicine.  At the time of the authority application, medical practitioners should request an appropriate maximum quantity based on IgE level and body weight (refer to the TGA-approved Product Information) to be administered every 2 to 4 weeks and up to 7 repeats to provide for an initial course sufficient for up to 32 weeks of therapy.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) Asthma Control Questionnaire (ACQ-5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and  (b) details (date and duration of treatment) of prior biological medicine treatment; and  (c) the IgE results and date; and  (d) if applicable, the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and  (e) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). | Compliance with Written Authority Required procedures |
|  | C15347 |  | Uncontrolled severe asthma  Continuing treatment  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received this drug as their most recent course of PBS-subsidised biological agent treatment for this condition in this treatment cycle; AND  Patient must have demonstrated or sustained an adequate response to PBS-subsidised treatment with this drug for this condition; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Patient must be aged 12 years or older.  An adequate response to omalizumab treatment is defined as:  (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR  (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline or an increase in ACQ-5 score from baseline less than or equal to 0.5, OR  (c) a reduction in the time-adjusted exacerbation rates compared to the 12 months prior to baseline (this criterion is only applicable for patients transitioned from the paediatric to the adolescent/adult restriction).  All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment, the assessment of oral corticosteroid dose or the assessment of time adjusted exacerbation rate should be made from 20 weeks after the first PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated.  The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. Where a response assessment is not undertaken and provided at the time of application, the patient will be deemed to have failed to respond to treatment with this drug.  Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient's response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment.  A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS-subsidised treatment with this biological medicine for severe asthma within the current treatment cycle.  At the time of the authority application, medical practitioners should request the appropriate quantity and number of repeats to provide for a continuing course of this biological medicine consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information), sufficient for up to 24 weeks of therapy.  The following information must be provided at the time of application and must be documented in the patient's medical records:  (a) Asthma Control Questionnaire (ACQ-5) score; and  (b) If applicable, maintenance oral corticosteroid dose; and  (c) For patients transitioned from the paediatric to the adolescent/adult restrictions, confirmation that the time-adjusted exacerbation rate has reduced.  The most recent Asthma Control Questionnaire (ACQ-5) score must be no more than 4 weeks old at the time of application. | Compliance with Authority Required procedures |
|  | C15350 |  | Uncontrolled severe allergic asthma  Initial treatment  Patient must have a diagnosis of asthma confirmed and documented in the patient's medical records by either: a (i) paediatric respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) paediatrician or general physician experienced in the management of patients with severe asthma in consultation with a respiratory physician, defined by at least one of the following standard clinical features: (a) forced expiratory volume (FEV1) reversibility, (b) airway hyperresponsiveness, (c) peak expiratory flow (PEF) variability; AND  Patient must have a duration of asthma of at least 1 year; AND  Patient must have past or current evidence of atopy, documented by either: (i) skin prick testing, (ii) an in vitro measure of specific IgE; AND  Patient must have total serum human immunoglobulin E of at least 30 IU/mL, measured no more than 12 months prior to the time of application; AND  Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented in the patient's medical records; AND  Patient must not receive more than 28 weeks of treatment under this restriction.  Patient must be aged 6 to less than 12 years.  Must be treated by a medical practitioner who is either a: (i) paediatric respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician.  Patient must be under the care of the same physician for at least 6 months.  Optimised asthma therapy includes:  (i) Adherence to optimal inhaled therapy, including high dose inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) therapy for at least six months. If LABA therapy is contraindicated, not tolerated or not effective, montelukast, cromoglycate or nedocromil may be used as an alternative;  AND  (ii) treatment with at least 2 courses of oral or IV corticosteroids (daily or alternate day maintenance treatment courses, or 3-5 day exacerbation treatment courses), in the previous 12 months, unless contraindicated or not tolerated.  If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications (including those specified in the relevant TGA-approved Product Information) and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application.  The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:  (a) An Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month (for children aged 6 to 10 years it is recommended that the Interviewer Administered version - the ACQ-IA be used),  AND  (b) while receiving optimised asthma therapy in the previous 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.  The Asthma Control Questionnaire (5 item version) or ACQ-IA assessment of the patient's response to this initial course of treatment, the assessment of oral corticosteroid dose, and the assessment of exacerbation rate should be made at around 24 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.  This assessment, which will be used to determine eligibility for continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with omalizumab.  A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.  At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab of up to 28 weeks, consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and  (b) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and  (c) the IgE result and date; and  (d) Asthma Control Questionnaire (ACQ-5) score; or  (e) Asthma Control Questionnaire interviewer administered version (ACQ-IA) score. | Compliance with Written Authority Required procedures |
|  | C15352 |  | Uncontrolled severe allergic asthma  Continuing treatment  Patient must have a documented history of severe allergic asthma; AND  Patient must have demonstrated or sustained an adequate response to PBS-subsidised treatment with this drug for this condition; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Must be treated by a medical practitioner who is either a: (i) paediatric respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician.  An adequate response to omalizumab treatment is defined as:  (a) a reduction in the Asthma Control Questionnaire (ACQ-5) or ACQ-IA score of at least 0.5 from baseline, OR  (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 or ACQ-IA score from baseline, OR  (c) a reduction in the time-adjusted exacerbation rates compared to the 12 months prior to baseline.  A measurement of response to the prior course of therapy must be provided at the time of application and should be used to determine eligibility for continuing treatment. The Asthma Control Questionnaire (5 item version) or Asthma Control Questionnaire interviewer administered version (ACQ-IA) assessment of the patient's response to the prior course of treatment, the assessment of systemic corticosteroid dose, and the assessment of time-adjusted exacerbation rate should be made from 20 weeks after the first dose of PBS-subsidised omalizumab so that there is adequate time for a response to be demonstrated. The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab.  Where a response assessment is not undertaken and provided at the time of application, the patient will be deemed to have failed to respond to treatment with omalizumab.  A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased.  At the time of the authority application, medical practitioners should request the appropriate quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information), sufficient for 24 weeks of therapy.  The following information must be provided at the time of application and must be documented in the patient's medical records:  (a) If applicable, the baseline and maintenance oral corticosteroid dose; and  (b) baseline and current Asthma Control Questionnaire (ACQ-5) date and score; or  (c) baseline and current Asthma Control Questionnaire interviewer administered version (ACQ-IA) date and score; and  (d) if applicable, confirmation that the time-adjusted exacerbation rate has reduced.  The most recent Asthma Control Questionnaire (ACQ-5) score or Asthma Control Questionnaire interviewer administered version (ACQ-IA) score must be no more than 4 weeks old at the time of application. | Compliance with Authority Required procedures |
|  | C15376 |  | Uncontrolled severe asthma  Balance of supply  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must have received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND  The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR  The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C15401 |  | Uncontrolled severe asthma  Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)  Must be treated by a medical practitioner who is either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma.  Patient must be under the care of the same physician for at least 6 months; OR  Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND  Patient must not have received PBS-subsidised treatment with a biological medicine for severe asthma; OR  Patient must have had a break in treatment of at least 12 months from the most recently approved PBS-subsidised biological medicine for severe asthma; AND  Patient must have a diagnosis of asthma confirmed and documented in the patient's medical records by either a: (i) respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) general physician experienced in the management of patients with severe asthma, defined by at least one of the following standard clinical features: (a) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), (b) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, (c) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR  Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma with the details documented in the patient's medical records; AND  Patient must have a duration of asthma of at least 1 year; AND  Patient must have past or current evidence of atopy that is no more than 1 year old at the time of application that is documented by either: (i) skin prick testing, (ii) an in vitro measure of specific IgE; AND  Patient must have total serum human immunoglobulin E of at least 30 IU/mL, measured no more than 12 months prior to the time of application; AND  Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented in the patient's medical records; AND  Patient must not receive more than 32 weeks of treatment under this restriction; AND  The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma.  Patient must be aged 12 years or older.  Optimised asthma therapy includes:  (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated;  AND  (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated.  If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application.  The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:  (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND  (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.  The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS-subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed.  This assessment, which will be used to determine eligibility for the first continuing treatment, should be conducted within 4 weeks of the last dose of biological medicine. Where a response assessment is not undertaken and provided, the patient will be deemed to have failed to respond to treatment with this drug.  If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for severe asthma within the same treatment cycle.  A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 4 biological medicines for severe asthma within the same treatment cycle.  The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle.  There is no limit to the number of treatment cycles that a patient may undertake in their lifetime.  At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.  A multidisciplinary severe asthma clinic team comprises of:  (i) A respiratory physician; and  (ii) A pharmacist, nurse or asthma educator.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).  The following must be provided at the time of application and documented in the patient's medical records:  (a) details of prior optimised asthma drug therapy (dosage, date of commencement, duration of therapy); and  (b) If applicable, details of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to standard therapy according to the relevant TGA-approved Product Information; and  (c) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and  (d) the IgE result and date; and  (e) Asthma Control Questionnaire (ACQ-5) score. | Compliance with Written Authority Required procedures |
|  | C15403 |  | Uncontrolled severe allergic asthma  Balance of supply in a patient aged 6 to 12 years  Must be treated by a medical practitioner who is either a: (i) paediatric respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician.  Patient must have received insufficient therapy with this drug under the Initial treatment restriction to complete 28 weeks treatment; OR  Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND  The treatment must provide no more than the balance of up to 28 weeks treatment available under the Initial restriction or up to 24 weeks treatment available under the Continuing restriction. | Compliance with Authority Required procedures |

1. Schedule 3, entry for Selinexor
   1. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C14022 | P14022 | Relapsed and/or refractory multiple myeloma Grandfather treatment ‑ Transitioning from non‑PBS to PBS‑subsidised supply ‑ Dose requirement of 80 mg, 60 mg or 40 mg per week Patient must have received non‑PBS‑subsidised treatment with this drug for this condition prior to 1 June 2023; AND Patient must have met all initial treatment PBS eligibility criteria applying to a non‑grandfathered patient prior to having commenced treatment with this drug, which are: (a) the condition was confirmed by histological diagnosis, (b) the treatment is/was being used as part of combination therapy limited to this drug in combination with either: (i) dexamethasone, (ii) dexamethasone plus bortezomib, (c) the condition progressed (see definition of progressive disease below) after at least one prior therapy, (d) the patient had never been treated with this drug; AND Patient must not have developed disease progression while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24‑hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo‑secretory and non‑secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Oligo‑secretory and non‑secretory patients are defined as having active disease with less than 10 g per L serum M protein. | Compliance with Authority Required procedures |

* 1. *omit:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | C14037 | P14037 | Relapsed and/or refractory multiple myeloma Grandfather treatment ‑ Transitioning from non‑PBS to PBS‑subsidised supply ‑ Dose requirement of 100 mg per week Patient must have received non‑PBS‑subsidised treatment with this drug for this condition prior to 1 June 2023; AND Patient must have met all initial treatment PBS eligibility criteria applying to a non‑grandfathered patient prior to having commenced treatment with this drug, which are: (a) the condition was confirmed by histological diagnosis, (b) the treatment is/was being used as part of combination therapy limited to this drug in combination with either: (i) dexamethasone, (ii) dexamethasone plus bortezomib, (c) the condition progressed (see definition of progressive disease below) after at least one prior therapy, (d) the patient had never been treated with this drug; AND Patient must not have developed disease progression while receiving treatment with this drug for this condition. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24‑hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo‑secretory and non‑secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Oligo‑secretory and non‑secretory patients are defined as having active disease with less than 10 g per L serum M protein. | Compliance with Authority Required procedures |